Amgen

Mentioned in 11 analyzed podcast episodes across 9 shows

Mentioned On

BioSpace 99% Invisible Pharma and BioTech Daily The a16z Show Huberman Lab Victor Davis Hanson: In His Own Words Mad Money w/ Jim Cramer BG2Pod with Brad Gerstner and Bill Gurley Chief Change Officer

Episode Mentions

BioSpace · May 13, 2026

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

“CEO Robert Bradway among top-paid executives; one of three Roberts leading major pharma companies”

FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program

View Analysis

99% Invisible · May 12, 2026

Ask Your Doctor About

“Referenced as pharmaceutical client that works with Brand Institute on drug naming projects”

Pharmaceutical brand naming processes and methodologiesFDA drug name approval requirements and regulationsMedication error prevention through visual name differentiation

View Analysis

Pharma and BioTech Daily · May 6, 2026

Sanofi Invests $294M in AI, FDA Approves Auvelity | Pharma and Biotech Daily

“Investing $300 million in Puerto Rico for biologics manufacturing and complex disease treatment”

AI Center of Excellence and Digital Transformation in Drug DevelopmentFDA Approval Processes and Regulatory ModernizationCAR-T Cell Therapy Expansion Beyond Oncology

View Analysis

Pharma and BioTech Daily · Apr 30, 2026

AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily

“Co-participant with AstraZeneca in FDA's real-time clinical trial data review pilot program”

FDA Real-Time Clinical Trial Review PilotAstraZeneca UK Investment and Drug PricingOncology Market Consolidation Strategy

View Analysis

The a16z Show · Apr 29, 2026

The Shift in Global Drug Development

“Mentioned alongside Gilead for hepatitis C drug development and competitive me-too drug strategies”

Clinical Trial Regulatory ReformDrug Approval Timelines and FDA ProcessGene Therapy and Cell Therapy Development

View Analysis

Pharma and BioTech Daily · Apr 29, 2026

AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily

“FDA proposed rescission of Tavneos approval due to alleged data manipulation and safety concerns”

FDA Drug Approval and RescissionData Integrity in Drug DevelopmentAI-Designed Therapeutics

View Analysis

Huberman Lab · Mar 9, 2026

Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson

“Pharmaceutical company leading development of bispecific T cell engager antibody therapies”

CAR-T cell therapyCRISPR gene editingCancer immunotherapy

View Analysis

Victor Davis Hanson: In His Own Words · Feb 10, 2026

Big Tech Wanted ‘Clean Energy.’ Ohio Gave Natural Gas | Rep. Troy Balderon

“Pharmaceutical company investing $300 million in Ohio's 12th congressional district with substantial power requirements”

Marcellus and Utica Shale natural gas extraction and reservesEnergy infrastructure permitting and interconnection queue delaysBaseload power generation requirements for AI data centers

View Analysis

Mad Money w/ Jim Cramer · Feb 5, 2026

Mad Money w/ Jim Cramer 2/4/26

“Established pharma company with solid earnings and buybacks; competing in GLP-1 space”

GLP-1 Drug Competition and Pricing StrategyEnterprise Software Industry Disruption by AIMarket Rotation from Growth to Value Stocks

View Analysis

BG2Pod with Brad Gerstner and Bill Gurley · Sep 11, 2025

Inside OpenAI Enterprise: Forward Deployed Engineering, GPT-5, and More | BG2 Guest Interview

OpenAI Enterprise PlatformForward Deployed EngineeringGPT-5 Development

View Analysis

Chief Change Officer · Jun 13, 2025

#411 Mark Bayer: From Ivory Tower to Power Play — Helping PhDs Get Heard (and Hired) — Part One

“Mentioned as a biotech company where PhD holders seek employment after leaving academic research.”

PhD Career Transitions to IndustryScientific Communication and PersuasionAcademic-to-Business Skills Gap

View Analysis